# US 2021/0241849 A1 · Method for personalized selection of a drug for a subject

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0241849 A1
- Document ID: US20210241849A1
- Status: Published application
- Kind: A1
- Application number: 17/200,447
- Filed: 2021-03-12
- Published: 2021-08-05
- Earliest claimed: 2013-08-19
- Assignees: Cipherome, Inc.
- Applicants: Cipherome, Inc.
- Inventors: Ju Han KIM; Su Yeon BAIK; Soo Youn LEE
- Web page: https://patentgrep.com/patent/US20210241849A1

## CPC

- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16C 20/30: Prediction of properties of chemical compounds, compositions or mixtures
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- G16B 20/40: Population genetics; Linkage disequilibrium
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a method and a system for selecting a drug customized on the basis of individual protein information by using individual genome sequences. The method and the system of the present invention can predict the individual side effects or danger of a certain drug by analyzing the sequence of the exon region of a gene encoding various proteins involved in the pharmacokinetics or pharmacodynamics of a predetermined drug or drug group, and have high reliability and are widely applicable and universal.

## Claims

### Claim 1

A method for personalizing selection of a drug for a subject using individual genome sequence variations of the subject, comprising:
obtaining, by a computer system, information regarding gene sequences of the subject for a set of genes involved in pharmacodynamics or pharmacokinetics of a drug group, wherein the drug group consists of a plurality of drugs;
determining, by the computer system, gene sequence variation information indicating variations present in the gene sequences involved in the pharmacodynamics or pharmacokinetics of the group;
for each gene of the set of genes:
determining, by the computer system, a gene sequence variation score;
for each protein encoded by a gene of the set of genes:
calculating, by the computer system, an individual protein damage score for the protein by using [Equation 2], wherein [Equation 2] is:
S
g
⁡
(
v
1
,
…
⁢
,
v
n
)
=
(
∏
i
=
1
n
⁢
⁢
v
i
w
i
)
1
/
∑
i
=
1
n
⁢
⁢
w
i
wherein Sg is the individual protein damage score of a protein encoded by a gene g, n is the number of target sequence variations for analysis among sequence variations of the gene g, vi is a gene sequence variation score of an ith gene sequence variation, and wi is a weighting assigned to the gene sequence variation score vi of the ith gene sequence variation;
for each drug in the drug group:
calculating, by the computer system, an individual drug score by using [Equation 4], wherein [Equation 4] is:
S
d
⁡
(
g
1
,
…
⁢
,
g
n
)
=
(
∏
i
=
1
n
⁢
⁢
g
i
w
i
)
1
/
∑
i
=
1
n
⁢
⁢
w
i
wherein Sd is the individual drug score of a drug d, n is a number of proteins encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d, gi is a protein damage score of a protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d, and wi is a weighting assigned to the protein damage score gi of the protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d;
ranking, by the computer system, drugs in the drug group by comparing the individual drug scores for the drugs; and
selecting a drug based on the ranking.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the plurality of drugs in the drug group have a same ATC code.

### Claim 3 (depends on 1)

The method according to claim 1,
wherein the gene sequence variation information means information about substitution, addition, or deletion of a base constituting an exon of a gene.

### Claim 4 (depends on 3)

The method according to claim 3,
wherein the substitution, addition, or deletion of the base results from structural abnormality including breakage, deletion, duplication, inversion, or translocation of a chromosome.

### Claim 5 (depends on 1)

The method according to claim 1,
wherein the gene sequence variation score is calculated by applying one or more algorithms selected from the group consisting of SIFT (Sorting Intolerant From Tolerant), PolyPhen (Polymorphism Phenotyping), PolyPhen-2, MAPP (Multivariate Analysis of Protein Polymorphism), Logre (Log R Pfam E-value), MutationAssessor, MutationTaster, MutationTaster2, PROVEAN (Protein Variation Effect Analyzer), PMut, Condel, GERP (Genomic Evolutionary Rate Profiling), GERP++, CEO (Combinatorial Entropy Optimization), SNPeffect, fathmm, and CADD (Combined Annotation-Dependent Depletion) to a gene sequence variation.

### Claim 6 (depends on 1)

The method according to claim 1,
wherein the weighting assigned to the gene sequence variation score or the weighting assigned to the protein damage score is determined considering a class of the protein, pharmacodynamic or pharmacokinetic classification of the protein, pharmacokinetic parameters of the enzyme protein of a corresponding drug, a population group, or a race distribution.

### Claim 7 (depends on 1)

The method according to claim 1, further comprising:
wherein the ranking step further comprises determining an order of priorities among drugs applicable to the subject by using the individual drug score; or wherein the selecting step further comprises determining whether or not to use the drugs applicable to the subject by using the individual drug score.

### Claim 8 (depends on 1)

The method according to claim 1,
wherein the drug group is information input by a user, information input from a prescription, or information input from a database including information about a drug effective in treating a predetermined disease.

### Claim 9 (depends on 1)

The method according to claim 1,
wherein the gene sequence variation information is acquired by a comparison analysis with a genome sequence of a reference group.

### Claim 10 (depends on 1)

The method according to claim 1, further comprising:
calculating a prescription score.

### Claim 11 (depends on 10)

The method according to claim 10,
wherein if two or more drugs are determined on the basis of an order of priority among drugs and need to be administered at the same time, the prescription score is calculated by summarizing drug scores determined with respect to the respective drugs.

### Claim 12 (depends on 1)

The method according to claim 1, further comprising:
providing one or more information selected from the group consisting of gene sequence variation information, a protein damage score, a drug score, and information used for calculation thereof.

### Claim 13 (depends on 1)

The method according to claim 1,
wherein the method is performed to prevent drug side effects.

### Claim 14

A computer-readable storage medium comprising stored instructions, wherein the instructions when executed by a processor cause the processor to perform steps comprising:
obtaining information regarding gene sequences of a subject for a set of genes involved in pharmacodynamics or pharmacokinetics of a drug group, wherein the drug group consists of a plurality of drugs;
determining gene sequence variation information indicating variations present in the gene sequences involved in the pharmacodynamics or pharmacokinetics of the drug group;
for each gene of the set of genes:
determining, by the computer system, a gene sequence variation score;
for each protein encoded by a gene of the set of genes
calculating an individual protein damage score for the protein by using [Equation 2], wherein [Equation 2] is:
S
g
⁡
(
v
1
,
…
⁢
,
v
n
)
=
(
∏
i
=
1
n
⁢
⁢
v
i
w
i
)
1
/
∑
i
=
1
n
⁢
⁢
w
i
wherein Sg is the individual protein damage score of a protein encoded by a gene g, n is the number of target sequence variations for analysis among sequence variations of the gene g, vi is a gene sequence variation score of an ith gene sequence variation, and wi is a weighting assigned to the gene sequence variation score vi of the ith gene sequence variation;
for each drug in the drug group:
calculating an individual drug score by using [Equation 4], wherein [Equation 4] is:
S
d
⁡
(
g
1
,
…
⁢
,
g
n
)
=
(
∏
i
=
1
n
⁢
⁢
g
i
w
i
)
1
/
∑
i
=
1
n
⁢
⁢
w
i
wherein Sd is the individual drug score of a drug d, n is a number of proteins encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d, gi is a protein damage score of a protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d, and wi is a weighting assigned to the protein damage score gi of the protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d;
ranking drugs in the drug group by comparing the individual drug scores for the drugs; and
selecting a drug based on the ranking.

### Claim 15 (depends on 14)

The computer-readable storage medium of claim 14, wherein the plurality of drugs in the drug group have a same ATC code.

### Claim 16

A system for providing information for personalizing drug selection using individual genome sequence variations, the system comprising:
a processor;
a computer readable storage medium comprising stored instructions, wherein the instructions when executed by a processor cause the processor to perform steps comprising:
obtaining information regarding gene sequences of a subject for a set of genes involved in pharmacodynamics or pharmacokinetics of a drug group, wherein the drug group consists of a plurality of drugs;
determining gene sequence variation information indicating variations present in the gene sequences involved in the pharmacodynamics or pharmacokinetics of the drug group;
for each gene of the set of genes:
determining, by the computer system, a gene sequence variation score;
for each protein encoded by a gene of the set of genes
calculating an individual protein damage score for the protein by using [Equation 2], wherein [Equation 2] is:
S
g
⁡
(
v
1
,
…
⁢
,
v
n
)
=
(
∏
i
=
1
n
⁢
⁢
v
i
w
i
)
1
/
∑
i
=
1
n
⁢
⁢
w
i
wherein Sg is the individual protein damage score of a protein encoded by a gene g, n is the number of target sequence variations for analysis among sequence variations of the gene g, vi is a gene sequence variation score of an ith gene sequence variation, and wi is a weighting assigned to the gene sequence variation score vi of the ith gene sequence variation;
for each drug in the drug group:
calculating an individual drug score by using [Equation 4], wherein [Equation 4] is:
S
d
⁡
(
g
1
,
…
⁢
,
g
n
)
=
(
∏
i
=
1
n
⁢
⁢
g
i
w
i
)
1
/
∑
i
=
1
n
⁢
⁢
w
i
wherein Sd is the individual drug score of a drug d, n is a number of proteins encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d, gi is a protein damage score of a protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d, and wi is a weighting assigned to the protein damage score gi of the protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug group d;
ranking drugs in the drug group by comparing the individual drug scores for the drugs; and
selecting a drug based on the ranking.

### Claim 17 (depends on 16)

The system for providing information for personalizing drug selection using individual genome sequence variations of claim 16, wherein the plurality of drugs in the drug group have a same ATC code

### Claim 18 (depends on 16)

The system for providing information for personalizing drug selection using individual genome sequence variations of claim 16, wherein the instructions when executed by the processor cause the processor to further perform steps comprising calculating a prescription score by summarizing drug scores determined with respect to respective drugs if two or more drugs are determined on the basis of an order of priority among drugs and need to be administered at the same time.

### Claim 19 (depends on 16)

The system for providing information for personalizing drug selection using individual genome sequence variations of claim 16, further comprising:
a user interface configured to provide drug scores of drugs or drug groups when a list of the drug groups is inputted by a user.

### Claim 20 (depends on 16)

The system for providing information for personalizing drug selection using individual genome sequence variations of claim 16, further comprising:
a display unit configured to display the protein damage or the drug score, or to display a calculation process, or information as a ground for the calculation.

### Claim 21 (depends on 16)

The system for providing information for personalizing drug selection using individual genome sequence variations of claim 16, wherein the gene sequence variation information, protein damage score, drug score and information as a ground for the calculation are stored in the computer-readable storage medium and are updated when the database is updated.
